BioCryst Appoints Dr. Donald Fong Chief Medical Officer
05 Septiembre 2024 - 6:00AM
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced
that Donald S. Fong, MD, MPH, has been appointed as the company’s
new chief medical officer, effective immediately.
Dr. Fong joins Dr. Helen Thackray, the company’s
chief research and development officer, and Dr. Bill Sheridan, the
company’s chief development officer, as physicians on the company’s
leadership team.
“We continue to advance our pipeline of novel
therapies to treat diseases with significant unmet needs, including
programs in Netherton syndrome and diabetic macular edema that we
expect will enter the clinic this year and next year, respectively.
Donald’s experience leading clinical research programs for various
diseases, coupled with his many years of experience and thought
leadership as an ophthalmologist, make him an excellent leader for
our global medical team as we continue to focus on bringing
potential life-changing therapies to patients who need them,”
Thackray said.
Dr. Fong joined BioCryst in April 2024 as vice
president of the ophthalmology therapeutic area, where he has
overseen clinical development of avoralstat, the company’s
investigational plasma kallikrein inhibitor for the treatment of
diabetic macular edema. He has more than 25 years of clinical
experience leading clinical trials, drug development and healthcare
organizations in both clinical and industry roles.
Prior to joining BioCryst, Dr. Fong served as
vice president of ophthalmology clinical development at Annexon
Biosciences, where he advanced the company’s asset to phase 3
trials in geographic atrophy. Prior to his time at Annexon, Dr.
Fong founded the clinical trials division at Kaiser Permanente
Southern California (KPSC) that oversaw trials for all medical and
surgical specialties and advanced the company’s oncology group to
become a leading national site. He also created and led KP’s
tele-ophthalmology/telemedicine program and is a clinical professor
at the KP School of Medicine. Dr. Fong has been an advisor to
numerous U.S. Food and Drug Administration (FDA) advisory
committees, in addition to serving as chair of the FDA’s
Dermatologic and Ophthalmic Drugs Advisory Committee. Dr. Fong
received his BA from Pomona College, his MD from UT Health San
Antonio and his MPH from the Harvard School of Public Health.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a
deep commitment to improving the lives of people living with
complement-mediated and other rare diseases. BioCryst leverages its
expertise in structure-guided drug design to develop first-in-class
or best-in-class oral small-molecule and protein therapeutics to
target difficult-to-treat diseases. BioCryst has commercialized
ORLADEYO® (berotralstat), the first oral, once-daily plasma
kallikrein inhibitor, and is advancing a pipeline of small-molecule
and protein therapies. For more information, please visit
www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:John Bluth+1 919 859
7910jbluth@biocryst.com
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024